ArticleLeukemia2024

Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma.

Brandon S Willis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.